Canβt wait to welcome you to Indiana University! Congratulations Dr Sugi!
Posts by Meena Madhur
ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism
#nephsky
www.ahajournals.org/doi/10.1161/...
#Takotsubo Syndrome: Expanding Insights, Unanswered Questions
By ACC Magazine
#CardioSky #MedSky
@accintouch.bsky.social
www.acc.org/Latest-in-Ca...
Congratulations to my friend and colleague @brandimwynne.bsky.social on this prestigious #award from ASPET! Well deserved!
Interesting interactive case presentation on an under-recognized cause of hypertension. @anandvaidya17.bsky.social @nejm.org
www.nejm.org/doi/10.1056/...
Congratulations @djfehrenbach.bsky.social ! This is a significant achievement and well deserved!
Nice email to open up! #SafetyFirst
π¨ π¬ Your #muscle remembers! π§ πͺ New π by Pilotto et al. reveals that high-intensity interval training imprints an epigenetic memory in human skeletal muscles π΄ββοΈπ Even after 3 months of rest! #HIIT #Epigenetics #MuscleMemory
#Kickback for the #holidayπ?!?
journals.physiology.org/doi/abs/10.1...
#HerAcademicVoice I want to highlight this website and initiative by my friend and colleague Dr Sotto. Check out these profiles of women of color and invite them to speak, collaborate, and learn from them. Spread the word.
www.sylksotto.com/heracademicv...
Hi. Please add me.
We strongly suggest that academic publishers and other platforms that host research rapidly implement a Share to Bluesky button for their articles. Here's how:
docs.bsky.app/docs/advance...
#AcademicSky #HigherEd #Altmetrics
Please add me and @amandadoranlab.bsky.social
Can you add me?
Please add me
#LBCT #SUMMIT trial #AHA24
π₯ Treatment with tirzepatide led to ‡οΈrisk of a composite of death from cardiovascular π« causes or worsening heart failure π placebo and improved health status in patients with HFpEF+obesity
π @NEJM www.nejm.org/doi/full/10....
Despite Primary Aldosteronism being the most common etiology of secondary HTN in middle-aged adults, <2% of the eligible population is ever screened!
Really need to start doing more PRA & Aldo levels on our patients with poorly-controlled HTN, risk factors (see below)
The 2024 ESC guideline says all-comers with HTN. Itβs been shown to be cost-effective across all-comers. I think Greg Hundemerβs work on the target organ effects of subclinical primary aldo is compelling π. Iβve been checking anyone with uncontrolled HTN
www.ahajournals.org/doi/10.1161/...